Vertex says interim ALYFTREK data show some children ages 2-5 regain pancreatic function
VRTX•Vertex said interim ALYFTREK study data showed some children with cystic fibrosis ages 2 to 5 regained pancreatic function. Use in patients under 6 remains investigational.
1. Interim study findings
Vertex said interim ALYFTREK data presented at the North American Cystic Fibrosis Conference showed some children with cystic fibrosis ages 2 to 5 regained pancreatic function. Some participants stopped pancreatic enzyme replacement therapy during the open-label extension; use in patients under 6 remains investigational.
